These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20237427)

  • 1. Gain-of-function c-CBL mutations associated with uniparental disomy of 11q in myeloid neoplasms.
    Ogawa S; Sanada M; Shih LY; Suzuki T; Otsu M; Nakauchi H; Koeffler HP
    Cell Cycle; 2010 Mar; 9(6):1051-6. PubMed ID: 20237427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.
    Sanada M; Suzuki T; Shih LY; Otsu M; Kato M; Yamazaki S; Tamura A; Honda H; Sakata-Yanagimoto M; Kumano K; Oda H; Yamagata T; Takita J; Gotoh N; Nakazaki K; Kawamata N; Onodera M; Nobuyoshi M; Hayashi Y; Harada H; Kurokawa M; Chiba S; Mori H; Ozawa K; Omine M; Hirai H; Nakauchi H; Koeffler HP; Ogawa S
    Nature; 2009 Aug; 460(7257):904-8. PubMed ID: 19620960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.
    Grand FH; Hidalgo-Curtis CE; Ernst T; Zoi K; Zoi C; McGuire C; Kreil S; Jones A; Score J; Metzgeroth G; Oscier D; Hall A; Brandts C; Serve H; Reiter A; Chase AJ; Cross NC
    Blood; 2009 Jun; 113(24):6182-92. PubMed ID: 19387008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
    Makishima H; Cazzolli H; Szpurka H; Dunbar A; Tiu R; Huh J; Muramatsu H; O'Keefe C; Hsi E; Paquette RL; Kojima S; List AF; Sekeres MA; McDevitt MA; Maciejewski JP
    J Clin Oncol; 2009 Dec; 27(36):6109-16. PubMed ID: 19901108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline CBL mutation associated with a noonan-like syndrome with primary lymphedema and teratoma associated with acquired uniparental isodisomy of chromosome 11q23.
    Hanson HL; Wilson MJ; Short JP; Chioza BA; Crosby AH; Nash RM; Marks KJ; Mansour S
    Am J Med Genet A; 2014 Apr; 164A(4):1003-9. PubMed ID: 24458550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer: More than kin and less than kind.
    Shannon K; Loh M
    Nature; 2009 Aug; 460(7257):804-7. PubMed ID: 19675635
    [No Abstract]   [Full Text] [Related]  

  • 7. CBL mutations in juvenile myelomonocytic leukemia and pediatric myelodysplastic syndrome.
    Shiba N; Kato M; Park MJ; Sanada M; Ito E; Fukushima K; Sako M; Arakawa H; Ogawa S; Hayashi Y
    Leukemia; 2010 May; 24(5):1090-2. PubMed ID: 20357823
    [No Abstract]   [Full Text] [Related]  

  • 8. Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms.
    Ogawa S; Shih LY; Suzuki T; Otsu M; Nakauchi H; Koeffler HP; Sanada M
    Clin Cancer Res; 2010 Aug; 16(15):3825-31. PubMed ID: 20547695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies.
    Dunbar AJ; Gondek LP; O'Keefe CL; Makishima H; Rataul MS; Szpurka H; Sekeres MA; Wang XF; McDevitt MA; Maciejewski JP
    Cancer Res; 2008 Dec; 68(24):10349-57. PubMed ID: 19074904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CBL mutation in chronic myelomonocytic leukemia secondary to familial platelet disorder with propensity to develop acute myeloid leukemia (FPD/AML).
    Shiba N; Hasegawa D; Park MJ; Murata C; Sato-Otsubo A; Ogawa C; Manabe A; Arakawa H; Ogawa S; Hayashi Y
    Blood; 2012 Mar; 119(11):2612-4. PubMed ID: 22138511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies.
    Adélaïde J; Gelsi-Boyer V; Rocquain J; Carbuccia N; Birnbaum DJ; Finetti P; Bertucci F; Mozziconacci MJ; Vey N; Birnbaum D; Chaffanet M
    Leukemia; 2010 Aug; 24(8):1539-41. PubMed ID: 20555362
    [No Abstract]   [Full Text] [Related]  

  • 12. Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders.
    Naramura M; Nadeau S; Mohapatra B; Ahmad G; Mukhopadhyay C; Sattler M; Raja SM; Natarajan A; Band V; Band H
    Oncotarget; 2011 Mar; 2(3):245-50. PubMed ID: 21422499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease.
    Bandi SR; Brandts C; Rensinghoff M; Grundler R; Tickenbrock L; Köhler G; Duyster J; Berdel WE; Müller-Tidow C; Serve H; Sargin B;
    Blood; 2009 Nov; 114(19):4197-208. PubMed ID: 19734451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.
    Schnittger S; Bacher U; Alpermann T; Reiter A; Ulke M; Dicker F; Eder C; Kohlmann A; Grossmann V; Kowarsch A; Kern W; Haferlach C; Haferlach T
    Haematologica; 2012 Dec; 97(12):1890-4. PubMed ID: 22733026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VAV1-Cre mediated hematopoietic deletion of CBL and CBL-B leads to JMML-like aggressive early-neonatal myeloproliferative disease.
    An W; Mohapatra BC; Zutshi N; Bielecki TA; Goez BT; Luan H; Iseka F; Mushtaq I; Storck MD; Band V; Band H
    Oncotarget; 2016 Sep; 7(37):59006-59016. PubMed ID: 27449297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired uniparental disomy and c-CBL mutation in myelodysplastic syndromes.
    Sanada M
    Rinsho Ketsueki; 2011 Jun; 52(6):342-9. PubMed ID: 21737985
    [No Abstract]   [Full Text] [Related]  

  • 17. Mutations of c-Cbl in myeloid malignancies.
    Katzav S; Schmitz ML
    Oncotarget; 2015 May; 6(13):10689-96. PubMed ID: 26028666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tracing the development of acute myeloid leukemia in CBL syndrome.
    Becker H; Yoshida K; Blagitko-Dorfs N; Claus R; Pantic M; Abdelkarim M; Niemöller C; Greil C; Hackanson B; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Döhner K; Schnittger S; Henneke P; Niemeyer CM; Flotho C; Pfeifer D; Ogawa S; Lübbert M
    Blood; 2014 Mar; 123(12):1883-6. PubMed ID: 24493670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
    Reindl C; Quentmeier H; Petropoulos K; Greif PA; Benthaus T; Argiropoulos B; Mellert G; Vempati S; Duyster J; Buske C; Bohlander SK; Humphries KR; Hiddemann W; Spiekermann K
    Clin Cancer Res; 2009 Apr; 15(7):2238-47. PubMed ID: 19276253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrity of the CBL gene in mature B-cell malignancies.
    McKeller MR; Robetorye RS; Dahia PL; Aguiar RC
    Blood; 2009 Nov; 114(19):4321-2. PubMed ID: 19892728
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.